About Us

We're a company founded to improve outcomes for patients with cancer.

ImmVirX seeks to advance a new generation of cancer treatments by developing a novel oncolytic immunotherapy that targets cancer indications with high unmet need.

Company Overview

ImmVirX was founded in late 2019 by the team from Viralytics, a clinical-stage ASX-listed oncolytic virus company acquired in June 2018 by Merck and Co. Inc. for A$502 million. We are developing proprietary bio-selected RNA viruses with the capacity to selectively infect and kill cancer cells while also inducing tumour inflammation and achieving immune cell infiltration – potentially leading to the generation of specific innate and adaptive immune responses against cancer cells.
Our viral candidates are intended to increase the anti-tumour activity of current cancer immunotherapies, including immune checkpoint inhibitors, CAR-Ts and other cell therapies, and are targeted against a range of difficult-to-treat cancers, including colorectal, gastric, hepatocellular and ovarian cancer.
Our Facilities

R&D Facilities

Our team is based in state-of-the-art R&D facilities at the Hunter Medical Research Institute (HMRI) and is supported by the University of Newcastle Research Associates (TUNRA) in Newcastle, New South Wales, Australia.
Our Team

Board & Management

The ImmVirX team comprises key directors and the executive and scientific staff from Viralytics.

Leveraging our leadership and experience in oncolytic viral therapies, we are actively progressing clinical trials, based on a body of pre-clinical and manufacturing data developed since operations commenced in 2020.
Meet the Team
In the News

View our recent news stories

Discover the latest news articles featuring ImmVirX, including research innovations, stories about our people and reports from the latest events.

View All Stories

Join Our Mailing List

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Our mission is to improve outcomes for patients with cancers in which immunotherapy treatments have limited effect